Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

221. Reproductive Health as a Marker of Subsequent Cardiovascular Disease: The Role of Estrogen

Reproductive Health as a Marker of Subsequent Cardiovascular Disease: The Role of Estrogen 27626902 2018 08 09 2018 11 13 2380-6591 1 7 2016 10 01 JAMA cardiology JAMA Cardiol Reproductive Health as a Marker of Subsequent Cardiovascular Disease: The Role of Estrogen. 776-777 10.1001/jamacardio.2016.2662 Manson JoAnn E JE Connors Center for Women's Health and Gender Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Woodruff Teresa K TK Division of Reproductive (...) Menopause. 2006 Mar-Apr;13(2):265-79 16645540 JAMA Cardiol. 2016 Oct 1;1(7):767-776 27627190 Biomarkers Cardiovascular Diseases Estrogen Receptor alpha Estrogen Replacement Therapy Estrogens Humans Menopause Receptors, Estrogen Reproductive Health Risk Factors Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported. 2016 10 21 6 0 2018 8 10 6 0 2016 9 15 6 0 ppublish 27626902 2551979 10.1001/jamacardio.2016.2662

JAMA cardiology2016 Full Text: Link to full Text with Trip Pro

222. An Electrocardiogram-Based Risk Equation for Incident Cardiovascular Disease From the National Health and Nutrition Examination Survey

An Electrocardiogram-Based Risk Equation for Incident Cardiovascular Disease From the National Health and Nutrition Examination Survey 27487404 2018 09 17 2018 11 13 2380-6591 1 7 2016 10 01 JAMA cardiology JAMA Cardiol An Electrocardiogram-Based Risk Equation for Incident Cardiovascular Disease From the National Health and Nutrition Examination Survey. 779-786 10.1001/jamacardio.2016.2173 Electrocardiography (ECG) may detect subclinical cardiovascular disease (CVD) in asymptomatic individuals (...) 11085961 Adult Aged Cardiovascular Diseases epidemiology Electrocardiography Female Humans Male Middle Aged Nutrition Surveys Risk Assessment Risk Factors 2016 10 21 6 0 2018 9 18 6 0 2016 8 4 6 0 ppublish 27487404 2540547 10.1001/jamacardio.2016.2173 PMC5881386 NIHMS952144

JAMA cardiology2016 Full Text: Link to full Text with Trip Pro

223. Omega-3 fatty acids and cardiovascular disease: an updated systematic review

Omega-3 fatty acids and cardiovascular disease: an updated systematic review Omega-3 fatty acids and cardiovascular disease: an updated systematic review Omega-3 fatty acids and cardiovascular disease: an updated systematic review Balk EM, Adam GP, Langberg V, Halladay C, Chung M, Lin L, Robertson S, Yip A, Steele D, Smith BT, Lau J, Lichtenstein AH, Trikalinos TA Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Balk EM, Adam GP, Langberg V, Halladay C, Chung M, Lin L, Robertson S, Yip A, Steele D, Smith BT, Lau J, Lichtenstein AH, Trikalinos TA. Omega-3 fatty acids and cardiovascular disease: an updated systematic review. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 223. 2016 Authors' objectives Evaluate the effect of omega−3 fatty acids (n-3 FA) on clinical and selected

Health Technology Assessment (HTA) Database.2016

224. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study.

Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. BACKGROUND: The optimum blood pressure target in hypertension remains debated, especially in coronary artery disease, given concerns for reduced myocardial perfusion if diastolic blood pressure is too low. We aimed to study the association between achieved blood pressure and cardiovascular outcomes in patients (...) with coronary artery disease and hypertension. METHODS: We analysed data from 22 672 patients with stable coronary artery disease enrolled (from Nov 26, 2009, to June 30, 2010) in the CLARIFY registry (including patients from 45 countries) and treated for hypertension. Systolic and diastolic blood pressures before each event were averaged and categorised into 10 mm Hg increments. The primary outcome was the composite of cardiovascular death, myocardial infarction, or stroke. Hazard ratios (HRs) were

Lancet2016 Full Text: Link to full Text with Trip Pro

225. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.

Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. IMPORTANCE: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors were recently approved for lowering low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia (FH) or atherosclerotic cardiovascular disease (ASCVD) and have potential for broad ASCVD prevention. Their long-term cost-effectiveness and effect (...) on total health care spending are uncertain. OBJECTIVE: To estimate the cost-effectiveness of PCSK9 inhibitors and their potential effect on US health care spending. DESIGN, SETTING, AND PARTICIPANTS: The Cardiovascular Disease Policy Model, a simulation model of US adults aged 35 to 94 years, was used to evaluate cost-effectiveness of PCSK9 inhibitors or ezetimibe in heterozygous FH or ASCVD. The model incorporated 2015 annual PCSK9 inhibitor costs of $14,350 (based on mean wholesale acquisition costs

JAMA2016 Full Text: Link to full Text with Trip Pro

226. Fruit Consumption and Cardiovascular Disease in China.

Fruit Consumption and Cardiovascular Disease in China. Fruit Consumption and Cardiovascular Disease in China. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27518673 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Aug 4;375(5):489. doi: 10.1056/NEJMc1606624. Fruit Consumption and Cardiovascular Disease in China. , , . Comment on [N Engl J Med. 2016] [N Engl J Med. 2016] [N Engl J Med. 2016] [N Engl J Med. 2016] PMID: 27518673 DOI: [Indexed for MEDLINE] Free full text Publication types MeSH terms Substance Full Text Sources Medical

NEJM2016

227. Fruit Consumption and Cardiovascular Disease in China.

Fruit Consumption and Cardiovascular Disease in China. Fruit Consumption and Cardiovascular Disease in China. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27518674 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Aug 4;375(5):487-8. doi: 10.1056/NEJMc1606624#SA1. Fruit Consumption and Cardiovascular Disease in China. 1 . 1 Clinical Nutrition Research Center, Singapore, Singapore mleowsj@massmed.org. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2016] PMID: 27518674 DOI: [Indexed for MEDLINE] Publication types MeSH terms

NEJM2016 Full Text: Link to full Text with Trip Pro

228. Fruit Consumption and Cardiovascular Disease in China.

Fruit Consumption and Cardiovascular Disease in China. Fruit Consumption and Cardiovascular Disease in China. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27518675 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Aug 4;375(5):488. doi: 10.1056/NEJMc1606624#SA2. Fruit Consumption and Cardiovascular Disease in China. 1 . 1 Tel Aviv University, Tel Aviv, Israel eran.kopel@gmx.com. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2016] PMID: 27518675 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substance Full Text

NEJM2016 Full Text: Link to full Text with Trip Pro

229. Fruit Consumption and Cardiovascular Disease in China.

Fruit Consumption and Cardiovascular Disease in China. Fruit Consumption and Cardiovascular Disease in China. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27518676 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Aug 4;375(5):488. doi: 10.1056/NEJMc1606624#SA3. Fruit Consumption and Cardiovascular Disease in China. 1 , 1 . 1 Soochow University, Suzhou, China qinliqiang@suda.edu.cn. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2016] PMID: 27518676 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substance Full Text

NEJM2016 Full Text: Link to full Text with Trip Pro

230. Blood pressure and complications in individuals with type 2 diabetes and no previous cardiovascular disease: national population based cohort study.

Blood pressure and complications in individuals with type 2 diabetes and no previous cardiovascular disease: national population based cohort study. OBJECTIVES: To compare the risk associated with systolic blood pressure that meets current recommendations (that is, below 140 mm Hg) with the risk associated with lower levels in patients who have type 2 diabetes and no previous cardiovascular disease. DESIGN: Population based cohort study with nationwide clinical registries, 2006-12. The mean (...) follow-up was 5.0 years. SETTING: 861 Swedish primary care units and hospital outpatient clinics. PARTICIPANTS: 187 106 patients registered in the Swedish national diabetes register who had had type 2 diabetes for at least a year, age 75 or younger, and with no previous cardiovascular or other major disease. MAIN OUTCOME MEASURES: Clinical events were obtained from the hospital discharge and death registers with respect to acute myocardial infarction, stroke, a composite of acute

BMJ2016 Full Text: Link to full Text with Trip Pro

232. Risk score overestimation: the impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern mult

Risk score overestimation: the impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern mult 27436865 2016 07 20 2017 03 31 1522-9645 38 8 2017 Feb 21 European heart journal Eur. Heart J. Risk score overestimation: the impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart (...) Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern multi-ethnic cohort. 598-608 10.1093/eurheartj/ehw301 To evaluate the 2013 American Heart Association (AHA)-American College of Cardiology (ACC)-Atherosclerotic Cardiovascular Disease (ASCVD) risk score among four different race/ethnic groups and to ascertain which factors are most associated with risk overestimation by the AHA-ACC-ASCVD score. The Multi-Ethnic Study of Atherosclerosis (MESA

EvidenceUpdates2016 Full Text: Link to full Text with Trip Pro

233. Impact of Replacing the Pooled Cohort Equation With Other Cardiovascular Disease Risk Scores on Atherosclerotic Cardiovascular Disease Risk Assessment (from the Multi-Ethnic Study of Atherosclerosis [MESA])

Impact of Replacing the Pooled Cohort Equation With Other Cardiovascular Disease Risk Scores on Atherosclerotic Cardiovascular Disease Risk Assessment (from the Multi-Ethnic Study of Atherosclerosis [MESA]) 27445216 2016 08 17 2017 01 25 1879-1913 118 5 2016 Sep 01 The American journal of cardiology Am. J. Cardiol. Impact of Replacing the Pooled Cohort Equation With Other Cardiovascular Disease Risk Scores on Atherosclerotic Cardiovascular Disease Risk Assessment (from the Multi-Ethnic Study (...) of Atherosclerosis [MESA]). 691-6 10.1016/j.amjcard.2016.06.015 S0002-9149(16)31036-0 The increase in statin eligibility by the new cholesterol guidelines is mostly driven by the Pooled Cohort Equation (PCE) criterion (≥7.5% 10-year PCE). The impact of replacing the PCE with either the modified Framingham Risk Score (FRS) or the Systematic Coronary Risk Evaluation (SCORE) on assessment of atherosclerotic cardiovascular disease (ASCVD) risk assessment and statin eligibility remains unknown. We assessed

EvidenceUpdates2016

234. High-density lipoprotein cholesterol (HDL-C) in cardiovascular disease: effect of exercise training

High-density lipoprotein cholesterol (HDL-C) in cardiovascular disease: effect of exercise training 28462120 2018 11 13 2213-4220 5 3 2016 Sep Integrative medicine research Integr Med Res High-density lipoprotein cholesterol (HDL-C) in cardiovascular disease: effect of exercise training. 212-215 10.1016/j.imr.2016.07.001 Decreases in high-density lipoprotein cholesterol (HDL-C) levels are associated with an increased risk of coronary artery disease (CAD), whereas increased HDL-C levels (...) are related to a decreased risk of CAD and myocardial infarction. Although HDL prevents the oxidation of low-density lipoprotein under normal conditions, it triggers a structural change, inhibiting antiarteriosclerotic and anti-inflammatory functions, under pathological conditions such as oxidative stress, inflammation, and diabetes. HDL can transform into various structures based on the quantitative reduction and deformation of apolipoprotein A1 and is the primary cause of increased levels

Integrative medicine research2016 Full Text: Link to full Text with Trip Pro

235. Androgen Deprivation Therapy–Induced Cardiovascular Disease

Androgen Deprivation Therapy–Induced Cardiovascular Disease 28717732 2017 07 19 2378-9506 2 6 2016 Dec Journal of global oncology J Glob Oncol Androgen Deprivation Therapy-Induced Cardiovascular Disease. 438 10.1200/JGO.2016.006015 Dhanushkodi Manikandan M Cancer Institute (WIA), Chennai, India. eng Journal Article 2016 07 27 United States J Glob Oncol 101674751 2378-9506 J Glob Oncol. 2016 Jul 27;2(6):439 28722032 The following represents disclosure information provided by authors

Journal of global oncology2016 Full Text: Link to full Text with Trip Pro

236. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care.

Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care. OBJECTIVE: To assess associations between risks of cardiovascular disease, heart failure, and all cause mortality and different diabetes drugs in people with type 2 diabetes, particularly newer agents, including gliptins and thiazolidinediones (glitazones). DESIGN: Open cohort study. SETTING: 1243 general practices contributing data to the QResearch database in England (...) . PARTICIPANTS: 469 688 people with type 2 diabetes aged 25-84 years between 1 April 2007 and 31 January 2015. EXPOSURES: Diabetes drugs (glitazones, gliptins, metformin, sulphonylureas, insulin, other) alone and in combination. MAIN OUTCOME MEASURE: First recorded diagnoses of cardiovascular disease, heart failure, and all cause mortality recorded on the patients' primary care, mortality, or hospital record. Cox proportional hazards models were used to estimate hazard ratios for diabetes treatments

BMJ2016 Full Text: Link to full Text with Trip Pro

237. Racial Differences in Atrial Fibrillation-Related Cardiovascular Disease and Mortality: The Atherosclerosis Risk in Communities (ARIC) Study

Racial Differences in Atrial Fibrillation-Related Cardiovascular Disease and Mortality: The Atherosclerosis Risk in Communities (ARIC) Study 27438320 2018 10 09 2018 11 13 2380-6591 1 4 2016 07 01 JAMA cardiology JAMA Cardiol Racial Differences in Atrial Fibrillation-Related Cardiovascular Disease and Mortality: The Atherosclerosis Risk in Communities (ARIC) Study. 433-41 10.1001/jamacardio.2016.1025 The adverse outcomes associated with atrial fibrillation (AF) have been studied (...) , heart failure, CHD, and mortality was considerably larger in black individuals than white individuals. These results indicate the vulnerability and increased risk in black individuals with AF. Continued investigation of racial differences in AF and its related adverse outcomes are essential to identify and mitigate racial disparities in the treatment of AF. Magnani Jared W JW Cardiology Section, Whitaker Cardiovascular Institute, Evans Department of Medicine, Boston University School of Medicine

JAMA cardiology2016 Full Text: Link to full Text with Trip Pro

238. The link between bone disease and cardiovascular complications in hemodialysis patients

The link between bone disease and cardiovascular complications in hemodialysis patients 27504162 2016 08 09 2018 11 13 2008-5842 8 6 2016 Jun Electronic physician Electron Physician The link between bone disease and cardiovascular complications in hemodialysis patients. 2483-8 10.19082/2483 The burden on the cardiovascular system is the main cause of mortality in chronic renal patients, and bone disease, which also may cause disability, is one of the most important complications in those (...) patients. The aim of this study was to determine the link between cardiovascular and bone disease, which frequently occur together. In this matched case-control study, 70 subjects were subjected for full laboratory assessment as well as estimation of parathyroid hormone (PTH) level, vitamin D level, complete echocardiography, and dual energy absorptiometry. Of the 70 patients, 50 were on regular hemodialysis, and there were 20 normal controls matched with the patients with respect to age and gender

Electronic physician2016 Full Text: Link to full Text with Trip Pro

239. Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients With Stable Coronary Heart Disease.

Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients With Stable Coronary Heart Disease. IMPORTANCE: Precise stratification of cardiovascular risk in patients with coronary heart disease (CHD) is needed to inform treatment decisions. OBJECTIVE: To derive and validate a score to predict risk of cardiovascular outcomes among patients with CHD, using large-scale analysis of circulating proteins. DESIGN, SETTING, AND PARTICIPANTS: Prospective cohort (...) with cardiovascular events after the second sample, absolute within-person annualized risk increased more for the 9-protein model (median, 1.86% [95% CI, 1.15%-2.54%]) than for the refit Framingham model (median, 1.00% [95% CI, 0.87%-1.19%]) (P = .002), while among 375 participants without cardiovascular events, both scores changed less and similarly (P = .30). CONCLUSIONS AND RELEVANCE: Among patients with stable CHD, a risk score based on 9 proteins performed better than the refit Framingham secondary event

JAMA2016 Full Text: Link to full Text with Trip Pro

240. Cardiovascular complications and risk of death in sickle-cell disease.

Cardiovascular complications and risk of death in sickle-cell disease. In sickle-cell disease, a point mutation in the β-globin chain causes haemoglobin to polymerise within erythrocytes during deoxygenation, altering red blood cell rheology and causing haemolysis. Improvements in health infrastructure, preventive care, and clinical treatments have reduced the morbidity and mortality of sickle-cell disease in developed countries. However, as these patients live longer, the chronic effects (...) , and epidemiology of major cardiovascular complications in patients with sickle-cell disease and discuss how screening and intervention could reduce their incidence. Copyright © 2016 Elsevier Ltd. All rights reserved.

Lancet2016